A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...

Merck (NYSE:MRK) stock in focus as the company partners with Jiangsu Hengrui in a $2B deal for heart disease therapy HRS-5346 ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

Merck KGaA fought for years to get the drug approved after rejection by ... which is associated with unpleasant gastrointestinal side effects. Moreover, it could also help defend Biogen’s ...

Biogen’s Tecfidera (dimethyl fumarate) is taken twice daily and is associated with unpleasant gastrointestinal side-effects. But Merck KGaA’s drug requires two short treatment courses ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of doravirine/islatravir met its primary efficacy endpoint. The first trial enrolled patients ...

The manufacturer of Vioxx, Merck & Co., argued that Vioxx ... surgeries or hospitalizations avoided by the gastrointestinal benefits of this drug. At the same time, we might be able to make ...

“I’m excited to see that DOR/ISL has potential as a new daily treatment option for people living with HIV who may benefit from this two-drug regimen.” Islatravir, Merck’s investigational ...

Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025 On Wednesday, Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of ...